Evaluation of Therapy for Lymphoma

Front, 1995, The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients, Semin Nucl Med, 25, 60, 10.1016/S0001-2998(05)80007-8 Jerusalem, 2003, PET scan imaging in oncology, Eur J Cancer, 39, 1525, 10.1016/S0959-8049(03)00374-5 Rini, 2002, F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin’s disease, Clin Nucl Med, 27, 572, 10.1097/00003072-200208000-00005 Kostakoglu, 2002, Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma, Cancer, 94, 879, 10.1002/cncr.10336 Wirth, 2002, Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma, Am J Med, 112, 262, 10.1016/S0002-9343(01)01117-2 Bar-Shalom, 2003, Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma, Radiology, 227, 353, 10.1148/radiol.2272020195 Friedberg, 2004, FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma, Leuk Lymphoma, 45, 85, 10.1080/1042819031000149430 Sasaki, 2002, Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma, Ann Nucl Med, 16, 337, 10.1007/BF02988618 Shen, 2002, Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma, Oncol Rep, 9, 321 Van Den Bossche, 2002, 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients, Nucl Med Commun, 23, 1079, 10.1097/00006231-200211000-00007 Jerusalem, 1999, Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 Jerusalem, 2003, Early detection of relapse by whole-body positron emission tomography (PET) in the follow-up of patients with Hodgkin’s disease (HD), Ann Oncol, 14, 123, 10.1093/annonc/mdg011 Elstrom, 2003, Utility of FDG-PET scanning in lymphoma by WHO classification, Blood, 101, 3875, 10.1182/blood-2002-09-2778 Jerusalem, 1999, Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, Nucl Med Commun, 20, 13, 10.1097/00006231-199901000-00004 Jerusalem, 2001, Positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin’s lymphoma (NHL), Ann Oncol, 825, 10.1023/A:1011169332265 Jerusalem, 2001, Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease, Haematologica, 86, 266 Jerusalem, 2002, Positron emission tomography in non-Hodgkin’s lymphoma (NHL), Clin Lymphoma, 3, 56, 10.3816/CLM.2002.n.012 Dobert, 2004, Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin’s and non-Hodgkin’s lymphoma, Q J Nucl Med Mol Imaging, 48, 33 Jerusalem G, Hustinx R: Nuclear Medicine, in Canellos G, Lister TA, Young B (eds): The Lymphomas (ed 2). New York, Elsevier (in press) Zijlstra, 2003, 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin’s lymphoma, Br J Haematol, 123, 454, 10.1046/j.1365-2141.2003.04617.x Jerusalem, 2003, Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin’s disease (Hd) and non-Hodgkin’s lymphoma (Nhl), Proc Am Soc Clin Oncol, 22, 572 Mikosch, 2003, Accuracy of whole-body 18F-FDG-PET for restaging malignant lymphoma, Acta Med Austr, 30, 41, 10.1046/j.1563-2571.2003.03003.x Hueltenschmidt, 2001, Whole body positron emission tomography in the treatment of Hodgkin disease, Cancer, 91, 302, 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4 Bangerter, 1999, Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment, Radiography, 5, 155, 10.1016/S1078-8174(99)90024-X Weihrauch, 2001, Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease, Blood, 98, 2930, 10.1182/blood.V98.10.2930 Panizo, 2004, Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin’s disease mediastinal masses, Leuk Lymphoma, 45, 1829, 10.1080/1042819042000223813 Glatz, 1996, Vortauschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET, Fortschr Rontgenstr, 165, 309, 10.1055/s-2007-1015764 Weinblatt, 1997, False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease, J Nucl Med, 38, 888 Sandherr, 2001, Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose, Ann Oncol, 12, 719, 10.1023/A:1011136324038 de Wit, 1997, Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma, Ann Oncol, 8, S57, 10.1093/annonc/8.suppl_1.S57 Cremerius, 1998, Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma, Nucl Med Commun, 19, 1055, 10.1097/00006231-199811000-00005 Weidmann, 1999, Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease, Leuk Lymph, 34, 545, 10.3109/10428199909058482 de Wit, 2001, 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma, Ann Oncol, 12, 29, 10.1023/A:1008357126404 Yoon, 2001, False-positive F-18 FDG gamma camera positron emission tomographic imaging resulting from inflammation of an anterior mediastinal mass in a patient with non-Hodgkin’s lymphoma, Clin Nucl Med, 26, 461, 10.1097/00003072-200105000-00022 Zinzani, 2004, Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients, Br J Cancer, 91, 850, 10.1038/sj.bjc.6602040 Dittmann, 2001, Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma, Oncol Rep, 8, 1393 de Hemricourt, 2003, Sarcoidosis and sarcoid-like reaction following Hodgkin’s disease. Report of two cases, Mol Imaging Biol, 5, 15, 10.1016/S1536-1632(02)00123-3 Bomanji, 2002, Challenging cases and diagnostic dilemmas: Case 2. Pitfalls of positron emission tomography for assessing residual mediastinal mass after chemotherapy for Hodgkin’s disease, J Clin Oncol, 20, 3347, 10.1200/JCO.2002.20.15.3347 Naumann, 2002, Simultaneous occurence of Hodgkin’s lymphoma and eosinophilic granuloma—a potential pitfall in PET imaging, Clin Lymphoma, 3, 121, 10.3816/CLM.2002.n.019 Cheong, 2003, Erythema nodosum associated with diffuse, large B-cell non-Hodgkin lymphoma detected by FDG PET, Clin Nucl Med, 28, 652, 10.1097/01.RLU.0000079389.14140.be Becherer, 2002, Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation, Leukemia, 16, 260, 10.1038/sj.leu.2402342 Lorenzen, 1999, Granulation tissue, Nuklearmedizin, 38, 333 Naumann, 2001, Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, Br J Haematol, 115, 793, 10.1046/j.1365-2141.2001.03147.x Armitage, 1986, Chemotherapy for diffuse large-cell lymphoma—rapidly responding patients have more durable remissions, J Clin Oncol, 4, 160, 10.1200/JCO.1986.4.2.160 Engelhard, 1991, Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas, Ann Oncol, 2, 177, 10.1093/annonc/2.suppl_2.177 Haq, 1994, Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma, J Clin Oncol, 12, 1074, 10.1200/JCO.1994.12.5.1074 Rahmouni, 1993, Lymphoma, Radiology, 188, 445, 10.1148/radiology.188.2.8327695 Front, 2000, Aggressive non-Hodgkin lymphoma, Radiology, 214, 253, 10.1148/radiology.214.1.r00ja03253 Janicek, 1997, Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy, J Clin Oncol, 15, 1631, 10.1200/JCO.1997.15.4.1631 Gasparini, 1998, Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin’s lymphoma, J Nucl Med, 39, 1586 Kaplan, 1990, Gallium-67 imaging, J Clin Oncol, 8, 1966, 10.1200/JCO.1990.8.12.1966 Romer, 1998, Positron emission tomography in non-Hodgkin’s lymphoma, Blood, 91, 4464 Mikhaeel, 2000, 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT, Leuk Lymphoma, 39, 543, 10.3109/10428190009113384 Jerusalem, 2000, Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma, Haematologica, 85, 613 Kostakoglu, 2002, PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease, J Nucl Med, 43, 1018 Spaepen, 2002, Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma, Ann Oncol, 13, 1356, 10.1093/annonc/mdf256 Torizuka, 2004, Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma, Eur J Nucl Med Mol Imaging, 31, 22, 10.1007/s00259-003-1333-8 Young, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 Spaepen, 2003, [(18)F]FDG PET monitoring of tumour response to chemotherapy, Eur J Nucl Med Mol Imaging, 30, 682, 10.1007/s00259-003-1120-6 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 Anselmo, 2000, Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease patients, Ann Hematol, 79, 79, 10.1007/s002770050014 Spaepen, 2003, Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation, Blood, 102, 53, 10.1182/blood-2002-12-3842 Cremerius, 2002, Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma, Bone Marrow Transplant, 30, 103, 10.1038/sj.bmt.1703607 Schot, 2003, Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma, Br J Haematol, 123, 282, 10.1046/j.1365-2141.2003.04593.x Filmont, 2003, Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation, Chest, 124, 608, 10.1378/chest.124.2.608 Coiffier, 1999, How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin’s lymphoma patients?, Ann Oncol, 10, 1141, 10.1023/A:1008308129857 Radford, 1988, The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease, J Clin Oncol, 6, 940, 10.1200/JCO.1988.6.6.940 Glenn, 1991, The residual mediastinal mass following radiation therapy for Hodgkin’s disease, Am J Clin Oncol, 14, 16, 10.1097/00000421-199102000-00004 Coiffier, 1991, Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs, J Clin Oncol, 9, 211, 10.1200/JCO.1991.9.2.211 Jochelson, 1985, The significance of the residual mediastinal mass in treated Hodgkin’s disease, J Clin Oncol, 3, 637, 10.1200/JCO.1985.3.5.637 Israel, 1988, Gallium 67 imaging in monitoring lymphoma response to treatment, Cancer, 61, 2439, 10.1002/1097-0142(19880615)61:12<2439::AID-CNCR2820611208>3.0.CO;2-Q Surbone, 1988, Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy, J Clin Oncol, 6, 1832, 10.1200/JCO.1988.6.12.1832 Canellos, 1988, Residual mass in lymphoma may not be residual disease, J Clin Oncol, 6, 931, 10.1200/JCO.1988.6.6.931 Segall, 2001, FDG PET imaging in patients with lymphoma, J Nucl Med, 42, 609 Zinzani, 1999, The role of positron emission tomography (PET) in the management of lymphoma patients, Ann Oncol, 10, 1181, 10.1023/A:1008327127033 Mikhaeel, 2000, 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas, Ann Oncol, 11, S147, 10.1093/annonc/11.suppl_1.S147 Foo, 2004, Positron emission tomography scanning in the assessment of patients with lymphoma, Intern Med J, 34, 388, 10.1111/j.1445-5994.2004.00614.x Spaepen, 2001, Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?, Br J Haematol, 115, 272, 10.1046/j.1365-2141.2001.03169.x Guay, 2003, Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation, J Nucl Med, 44, 1225 Spaepen, 2001, Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma, J Clin Oncol, 19, 414, 10.1200/JCO.2001.19.2.414 Maisey, 2000, Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?, Eur J Cancer, 36, 200, 10.1016/S0959-8049(99)00249-X Cremerius, 2001, Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma, Nuklearmedizin, 40, 23, 10.1055/s-0038-1623988 Lavely, 2003, FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy, Int J Radiat Oncol Biol Phys, 57, 307, 10.1016/S0360-3016(03)00599-6 Lang, 2001, Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin’s disease, Strahlenther Onkol, 177, 138, 10.1007/PL00002394 Cremerius, 1999, Clinical value of FDG PET for therapy monitoring of malignant lymphoma—results of a retrospective study in 72 patients, Nuklearmedizin, 38, 24 Torizuka, 2000, Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy, J Nucl Med, 41, 999 Jerusalem G, Hustinx R, Beguin Y, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for staging and response assessment in Hodgkin’s disease, in Colombus F (ed): Progress in Hodgkin’s Disease Research. Nova Science (in press)